<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551885</url>
  </required_header>
  <id_info>
    <org_study_id>FT516-102</org_study_id>
    <nct_id>NCT04551885</nct_id>
  </id_info>
  <brief_title>FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fate Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in&#xD;
      subjects with advanced solid tumors. The study will consist of a dose-escalation stage and an&#xD;
      expansion stage where participants will be enrolled into indication-specific cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 7, 2020</start_date>
  <completion_date type="Anticipated">August 2037</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities within each dose level cohort</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of dose-limiting toxicities within each dose level cohort</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature and severity of adverse events</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed duration of response (DOR)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Duration of the first occurrence of a documented, objective response until the time of disease progression, relapse or death from any cause, whichever occurs first, per iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Proportion of subjects with Stable Disease more than 6 months, Partial Response or Complete Response, per iRECIST response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>The time from first dose of lympho-conditioning to disease progression or to the day of death for any reason, whichever occurs first, per iRECIST response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>The time from first dose of lympho-conditioning to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of PK of FT516 in peripheral blood</measure>
    <time_frame>Study Days 1, 2, 4, 8, 11, 18, 22, 29</time_frame>
    <description>The pharmacokinetics of FT516 in peripheral blood will be reported as the relative percentage of product (FT516) DNA versus patient DNA (% chimerism) measured from blood samples at the specified time points</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>FT516 in combination with avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FT516</intervention_name>
    <description>Experimental Interventional Therapy</description>
    <arm_group_label>FT516 in combination with avelumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Monoclonal antibody</description>
    <arm_group_label>FT516 in combination with avelumab</arm_group_label>
    <other_name>Bavencio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>FT516 in combination with avelumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Lympho-conditioning agent</description>
    <arm_group_label>FT516 in combination with avelumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>Biologic response modifier</description>
    <arm_group_label>FT516 in combination with avelumab</arm_group_label>
    <other_name>Proleukin</other_name>
    <other_name>Aldesleukin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally advanced or metastatic solid tumor malignancies that have relapsed or&#xD;
             progressed after at least one line of therapy and where the following anti-PD-L1 are&#xD;
             approved: avelumab, atezolizumab or durvalumab&#xD;
&#xD;
          -  Capable of giving signed informed consent&#xD;
&#xD;
          -  Aged ≥ 18 years old&#xD;
&#xD;
          -  Willingness to comply with study procedures and duration&#xD;
&#xD;
          -  Measurable disease per iRECIST&#xD;
&#xD;
          -  Contraceptive use for women and men as defined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  ECOG performance status ≥ 2&#xD;
&#xD;
          -  Evidence of insufficient organ function&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Receipt of therapy within 2 weeks prior to Day 1 or five half-lives, whichever is&#xD;
             shorter or any investigational therapy within 28 days prior to Day 1&#xD;
&#xD;
          -  Known active central nervous system (CNS) involvement by malignancy&#xD;
&#xD;
          -  Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis or&#xD;
             neurodegenerative disease or receipt of medications for these conditions&#xD;
&#xD;
          -  Currently receiving or likely to require immunosuppressive therapy&#xD;
&#xD;
          -  Known active infections with Hepatitis B, Hepatitis C or HIV&#xD;
&#xD;
          -  Live vaccine within 6 weeks prior to start of lympho-conditioning&#xD;
&#xD;
          -  Known allergy to albumin (human) or DMSO&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Chou, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fate Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center/John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zhu H, Blum RH, Bjordahl R, Gaidarova S, Rogers P, Lee TT, Abujarour R, Bonello GB, Wu J, Tsai PF, Miller JS, Walcheck B, Valamehr B, Kaufman DS. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood. 2020 Feb 6;135(6):399-410. doi: 10.1182/blood.2019000621.</citation>
    <PMID>31856277</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-L1</keyword>
  <keyword>cellular therapy</keyword>
  <keyword>NK cells</keyword>
  <keyword>urothelial cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>merkel cell carcinoma</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>triple negative breast cancer</keyword>
  <keyword>immune checkpoint inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

